Published: May 11, 2021 BALTIMORE, May 11, 2021 (GLOBE NEWSWIRE) -- RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today that it held an inaugural joint meeting of its Board of Directors and Advisory Board on May 10, 2021. The newly expanded Board of Directors and Advisory Board will work alongside the leadership team to advance RNADD's proprietary Antisense RNA diagnostic platform to prevent the transmission of infectious diseases. "We are honored to have such a highly skilled, well-regarded group of industry veterans to comprise our Board of Directors and Advisory Board," said Allan Oberman, co-Founder and Chairman of RNADD. "Representing decades of experience in healthcare, finance, business, and more, they will be instrumental as we execute on our strategy to deliver lab-based, point-of-care and home-use diagnostics for the affordable, rapid detection of COVID-19 and beyond."